Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous tenocyte therapy
- Development stage
- Unknown
- Lead developer
- Orthocell
- Modality
- Cell Therapies
- Administration
- Intralesional
01
Overview
Autologous tenocyte therapy, branded as Ortho-ATI, is a cell-based biologic therapy developed by Orthocell for the treatment of chronic, treatment-resistant tendon injuries. The procedure involves a two-stage process: first, a biopsy of healthy tendon tissue (typically from the patella) is harvested from the patient; second, the tenocytes (tendon-derived cells) are isolated and expanded in a GMP-certified laboratory over 4–6 weeks. The expanded autologous cells are then injected back into the patient's damaged tendon under ultrasound guidance. The therapeutic goal is to restore the structural integrity and function of the degenerated tendon by stimulating the production of new collagen and extracellular matrix. It is primarily indicated for lateral epicondylitis (tennis elbow) and other forms of tendinopathy.
- Brand names
- Ortho-ATIOrthoATI
- Other names
- autologous tenocyte implantationATI
Beyond the preview
Go deeper on autologous tenocyte therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous tenocyte therapy.